Contribute Try STAT+ Today

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of maple bourbon for the occasion. Spring has sprung, after all. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. …

U.S. authorities recommended that states stop using the Johnson & Johnson (JNJ) Covid-19 vaccine while an investigation is conducted into six rare but serious cases of clotting problems that were reported among women who received the vaccine, STAT writes. The clotting issue is similar to the one reported after use of the AstraZeneca (AZN) shot, which has not been authorized for use in the U.S. A special meeting of government advisers will be held Wednesday to review the data around the issue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Given the lead item about hold on the distribution of the J&J one-shot vaccine, the timing of “Don’t take us for granted” by PhRMA turns out to be a bit off? One observes they may want the public to forget?

Comments are closed.